|
| Code | Diagnosis | Comment | Score |
| anonymous | Papillary adenocarcinoma of epididymus (100%) | nil | 50 |
| anonymous | embryonic carcinoma | nil | 30 |
| anonymous | Adenocarcinoma, favour metastatic, 100% | For clinical correlation | 90 |
| anonymous | Adenocarcinoma, differential diagnoses: Primary epididymal adenocarcinoma (30%) Metastatic adenocarcinoma, especially prostatic adenocarcinoma (70%) | Immunohistochemical studies for Prostatic specific antigen, TTF1, and review patient history and serologic tumor marker profile. | 100 |
| anonymous | Adenocarcinoma reminiscent of ductal type prostatic adenocarcinoma. | To exclude a prostatic primary. The tumor should be PSA+, AMACR+, inhibin-. | 100 |
| anonymous | Adenocarcinoma with prominent papillary pattern | Clinicoradiological correlation +/- immunohistochemistry are required to differentiate between primary and metastatic adenocarcinoma. Primary tumors with such morphology include paratesticular serous papillary carcinoma, epididymal adenocarcinoma and high-grade mesothelioma of tunica vaginalis (BerEP4 -ve, calretinin +ve, D2-40 -ve) Metastatic tumors from other sites also need to be considered, particularly prostatic primary (in view of prominent nucleoli; PSA +ve). | 100 |
| anonymous | Testis tumour - Adenocarcinoma 100% | The tumour growth has conspicuous papillary configuration, cells being tall columnar and nuclear anaplasia with macronucleoli. But unlikely germ cell or Sertoli cell types of neoplasm. Suspicious of metastasis (?prostate ?lung). Immunostains CD117, inhibin, SALL4, PSA, TTF1 etc required. | 100 |
| anonymous | Papillary adenocarcinoma, need to exclude metastasis from other organ 100% e.g. prostate | perform immunostains PSA | 100 |
| anonymous | Adenocarcinoma of paratesticular tissues. Need to consider adenocarcinoma of epididymis and metastatic adenocarcinoma (especially from prostate) 100%. | Clinical correlation and immunohistochemical studies are needed to exclude metastatic adenocarcinoma. | 100 |
| anonymous | Embryonal carcinoma. | Need to perform immunohistochemistry including CD30, OCT3/4 to confirm the diagnosis. | 30 |
| anonymous | TESTIS tumor - ADENOCARCINOMA, high grade cytology. Differential diagnoses include adenocarcinoma of epididymis/rete testis or metastatic adenocarcinoma. Correlation with clinical history and a panel of immunostains (e.g. CK7, CK20, TTF-1, PSA) to exclude possible metastasis are required. | nil | 100 |
| anonymous | Adenocarcinoma. | Differential diagnosis includes primary testicular carcinoma and metastatic carcinoma from other organs, such as prostate. Please correlate with clinical findings. | 90 |
| anonymous | Adenocarcinoma. The differential diagnosis includes metastatic adenocarcinoma (80%) and primary adenocarcinoma of rete testis (20%). | Correlation with clinical history is necessary to look for evidence of primary, such as prostate and lung. Immunohistochemical staining would be performed, such as PSA (for prostatic primary) and TTF-1 (for lung primary). If the tumour is PSA positive with known history of prostatic carcinoma, the overall features would favour metastatic ductal adenocarcinoma of prostate. If no extratesticular primary is detected, additional sections would be necessary to evaluate its relationship with the rete testis for the possibility of primary tumour. | 100 |
| anonymous | adenocarcinoma with papillary pattern, involving paratesticular area, need to exclude metastasis before diagnosis as primary from epididymis or rete testis (100%) | nil | 90 |
| anonymous | Papillary adenocarcinoma in a background of hyalinized atrophic seminiferous tubules of testis (100%). Need clinicopathological correlation for specific diagnosis. Secondary carcinoma more common than primary. Metastasis from prostatic duct adenocarcinoma (positive for prostatic acid phosphatase, prostatic specific antigen, P501S) should be considered. Differential diagnoses would include metastasis from high grade papillary carcinoma of urinary bladder (positive for thrombomodulin, CK7, HMWCK, p63) and primary tumor such as adenocarcinoma of rete-testis/epididymis, etc. | nil | 100 |
| anonymous | PAPILLARY ADENOCARCINOMA | nil | 50 |
| anonymous | Serous papillary cystadenocarcinoma 100% | nil | 50 |
| anonymous | Adenocarcinoma, favour metastasis. | Perform a panel of immunohistochemical stains (eg. CK7, CK20, PSA and TTF-1) for primary site. Prostatic origin has to be considered in view of the presence of prominent nucleoli. | 100 |